{
  "id": "Prostate_Cancer_Risk_Classification.v0.0.3-draft",
  "gdl_version": "2.1",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "name": "Kevin Arjona",
      "email": "kevin.arjona@cambio.se",
      "organisation": "Cambio CDS",
      "date": "2025-07-18"
    },
    "lifecycle_state": "DRAFTED",
    "details": {
      "en": {
        "id": "en",
        "purpose": "To automate the calculation of the prostate cancer risk group to support clinical decision-making based on the swedish national guidelines.",
        "keywords": [
          "national guidelines",
          "RCC",
          "PSA",
          "ISUP",
          "Gleason score",
          "T-stage",
          "risk",
          "cancer",
          "prostate"
        ],
        "use": " Use in patients with prostate cancer confirmed to be without distant metastases (M0 stage).",
        "misuse": "Not to be used for patients with known metastatic disease (M1), recurrent prostate cancer after primary treatment, or for assessing the risk of other types of cancer. Do not use if any of the mandatory input parameters (T-stage, Gleason, PSA) are unknown.",
        "copyright": "© Cambio CDS"
      }
    },
    "other_details": {
      "references": "Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013 Dec;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033. Epub 2013 Mar 23. PMID: 23541457.\n\nGnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med. 2018 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5. PMID: 29490658; PMCID: PMC5831573.\n\n",
      "en": "Applies the Swedish National Guidelines to classify localized prostate cancer into Very low, Low, Favorable Intermediate, Unfavorable Intermediate, High, or Very High risk groups based on recorded clinical parameters."
    }
  },
  "definition": {
    "data_bindings": {
      "gt0018": {
        "id": "gt0018",
        "model_id": "openEHR-EHR-EVALUATION.prostate_cancer_risk_group_assessment.v0",
        "template_id": "openEHR-EHR-EVALUATION.prostate_cancer_risk_group_assessment.v0",
        "type": "INPUT",
        "elements": {
          "gt0019": {
            "id": "gt0019",
            "path": "/data[at0001]/items[at0002]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0003",
              "local::at0004",
              "local::at0005",
              "local::at0006",
              "local::at0007"
            ]
          },
          "gt0020": {
            "id": "gt0020",
            "path": "/data[at0001]/items[at0008]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0009",
              "local::at0010",
              "local::at0011",
              "local::at0012",
              "local::at0013",
              "local::at0014"
            ]
          },
          "gt0021": {
            "id": "gt0021",
            "path": "/data[at0001]/items[at0015]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0016",
              "local::at0017",
              "local::at0018",
              "local::at0019"
            ]
          },
          "gt0022": {
            "id": "gt0022",
            "path": "/data[at0001]/items[at0020]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0021",
              "local::at0022"
            ]
          },
          "gt0023": {
            "id": "gt0023",
            "path": "/data[at0001]/items[at0023]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0021",
              "local::at0022"
            ]
          },
          "gt0024": {
            "id": "gt0024",
            "path": "/data[at0001]/items[at0026]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0021",
              "local::at0022"
            ]
          }
        }
      },
      "gt0025": {
        "id": "gt0025",
        "model_id": "openEHR-EHR-EVALUATION.prostate_cancer_risk_group_assessment.v0",
        "template_id": "openEHR-EHR-EVALUATION.prostate_cancer_risk_group_assessment.v0",
        "type": "OUTPUT",
        "elements": {
          "gt0026": {
            "id": "gt0026",
            "path": "/data[at0001]/items[at0030]",
            "data_type": "DV_CODED_TEXT"
          }
        }
      }
    },
    "rules": {
      "gt0012": {
        "id": "gt0012",
        "priority": 6,
        "when": [
          "$gt0019|T-stage|==local::at0003|T1c|",
          "$gt0020|Gleason score|==local::at0009|6 (ISUP 1)|",
          "$gt0021|PSA|==local::at0016|< 10 µg/l|",
          "$gt0022|PSA density < 0.15 ug/l/cm3|==local::at0021|Yes|",
          "$gt0023|Histological findings ≤ 8 mm cancer in total in 1–4 of 8–12 systematic biopsy cores|==local::at0021|Yes|"
        ],
        "then": [
          "$gt0026|Risk group|=local::at0031|Very low risk|"
        ]
      },
      "gt0013": {
        "id": "gt0013",
        "priority": 5,
        "when": [
          "$gt0019|T-stage|==local::at0004|T1-T2a|",
          "$gt0020|Gleason score|==local::at0009|6 (ISUP 1)|",
          "$gt0021|PSA|==local::at0016|< 10 µg/l|",
          "$gt0022|PSA density < 0.15 ug/l/cm3|==local::at0022|No|",
          "$gt0023|Histological findings ≤ 8 mm cancer in total in 1–4 of 8–12 systematic biopsy cores|==local::at0022|No|"
        ],
        "then": [
          "$gt0026|Risk group|=local::at0032|Low risk|"
        ]
      },
      "gt0014": {
        "id": "gt0014",
        "priority": 4,
        "when": [
          "$gt0019|T-stage|==local::at0005|T2b/T2c|||$gt0020|Gleason score|==local::at0010|7 (3+4) (ISUP 2)|||$gt0021|PSA|==local::at0017|10–19 µg/l|"
        ],
        "then": [
          "$gt0026|Risk group|=local::at0033|Favorable intermediate risk|"
        ]
      },
      "gt0015": {
        "id": "gt0015",
        "priority": 3,
        "when": [
          "($gt0019|T-stage|==local::at0005|T2b/T2c|&&$gt0020|Gleason score|==local::at0010|7 (3+4) (ISUP 2)|)||($gt0019|T-stage|==local::at0005|T2b/T2c|&&$gt0021|PSA|==local::at0017|10–19 µg/l|)||($gt0020|Gleason score|==local::at0010|7 (3+4) (ISUP 2)|&&$gt0021|PSA|==local::at0017|10–19 µg/l|)||local::at0012|7 (4+3) (ISUP 3)|||local::at0011|7 (3+4) (ISUP 2)  in more than half of systematic biopsy specimens|"
        ],
        "then": [
          "$gt0026|Risk group|=local::at0034|Unfavorable intermediate risk|"
        ]
      },
      "gt0016": {
        "id": "gt0016",
        "priority": 2,
        "when": [
          "$gt0019|T-stage|==local::at0006|T3a|||$gt0024|Strong suspicion of extraprostatic growth on MRI (EPE/SVI 5)|==local::at0021|Yes|||$gt0020|Gleason score|==local::at0013|8 (ISUP 4)|||$gt0021|PSA|==local::at0018|20–39 µg/l|"
        ],
        "then": [
          "$gt0026|Risk group|=local::at0035|High risk|"
        ]
      },
      "gt0017": {
        "id": "gt0017",
        "priority": 1,
        "when": [
          "$gt0019|T-stage|==local::at0006|T3a|&&$gt0024|Strong suspicion of extraprostatic growth on MRI (EPE/SVI 5)|==local::at0021|Yes|||($gt0019|T-stage|==local::at0006|T3a|&&$gt0020|Gleason score|==local::at0013|8 (ISUP 4)|)||$gt0019|T-stage|==local::at0006|T3a|&&$gt0021|PSA|==local::at0018|20–39 µg/l|||$gt0024|Strong suspicion of extraprostatic growth on MRI (EPE/SVI 5)|==local::at0021|Yes|&&$gt0020|Gleason score|==local::at0013|8 (ISUP 4)|||$gt0024|Strong suspicion of extraprostatic growth on MRI (EPE/SVI 5)|==local::at0021|Yes|&&$gt0021|PSA|==local::at0018|20–39 µg/l|||$gt0020|Gleason score|==local::at0013|8 (ISUP 4)|&&$gt0021|PSA|==local::at0018|20–39 µg/l|",
          "$gt0019|T-stage|==local::at0007|T3b/T4|||$gt0020|Gleason score|==local::at0010|7 (3+4) (ISUP 2)|||$gt0021|PSA|==local::at0019|≥ 40 µg/l|"
        ],
        "then": [
          "$gt0026|Risk group|=local::at0036|Very high risk|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "Prostate Cancer Risk Group Classification",
            "description": "Applies the Swedish National Guidelines to classify localized prostate cancer into risk groups based on recorded clinical parameters."
          },
          "gt0012": {
            "id": "gt0012",
            "text": "Set very low risk",
            "description": ""
          },
          "gt0013": {
            "id": "gt0013",
            "text": "Set low Risk",
            "description": ""
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Set favorable intermediate risk",
            "description": ""
          },
          "gt0015": {
            "id": "gt0015",
            "text": "Set unfavorable intermediate risk",
            "description": ""
          },
          "gt0016": {
            "id": "gt0016",
            "text": "Set high risk",
            "description": ""
          },
          "gt0017": {
            "id": "gt0017",
            "text": "Set very high risk",
            "description": ""
          },
          "gt0018": {
            "id": "gt0018",
            "text": "openEHR-EHR-EVALUATION.prostate_cancer_risk_group_assessment.v0"
          },
          "gt0019": {
            "id": "gt0019",
            "text": "T-stage"
          },
          "gt0020": {
            "id": "gt0020",
            "text": "Gleason score"
          },
          "gt0021": {
            "id": "gt0021",
            "text": "PSA"
          },
          "gt0022": {
            "id": "gt0022",
            "text": "PSA density < 0.15 ug/l/cm3"
          },
          "gt0023": {
            "id": "gt0023",
            "text": "Histological findings ≤ 8 mm cancer in total in 1–4 of 8–12 systematic biopsy cores"
          },
          "gt0024": {
            "id": "gt0024",
            "text": "Strong suspicion of extraprostatic growth on MRI (EPE/SVI 5)"
          },
          "gt0025": {
            "id": "gt0025",
            "text": "openEHR-EHR-EVALUATION.prostate_cancer_risk_group_assessment.v0"
          },
          "gt0026": {
            "id": "gt0026",
            "text": "Risk group"
          }
        }
      }
    }
  }
}